Drug Trial Radar · NCT06769048
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
Last checked: Nov 20, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
150
Actual
Start
Jan 31, 2025
Primary completion
Dec 22, 2026
Study completion Jan 5, 2027
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jan 10, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people with geographic atrophy and to find the most suitable dose. This study has 4 treatment groups. Participants are put into groups randomly, which means by chance. Initially participants can join a BI 1584862 and a placebo group; then more participants are put randomly in 2 additional BI 1584862 groups and a placebo group. Participants are in the study for 1 year. During this time, they visit the study site 13 times. At the visits, doctors check the severity of participants' eye disease and collect information on any health problems. They take detailed pictures of the back of the eye, the retina, with imaging methods called fundus autofluorescence (FAF), near-infrared reflectance (NIR), and optical coherence tomography (OCT). They measure areas of the retina that appear healthy (bright) or start to waste away (dark, atrophy). The changes over time are then compared between the treatment groups.
Conditions
- Geographic Atrophy
Interventions
Placebo-matching BI 1584862Drug
Placebo-matching BI 1584862
BI 1584862Drug
BI 1584862
Primary outcomes
What the sponsor says the trial is designed to measure.
- Slope of change from baseline in square root transformed geographic atrophy (GA) area as measured by fundus autofluorescence (FAF) over a treatment period of up to 50 weeks (expressed in mm/year) in the study eyeTime frame: Up to week 50.
Locations
44 sites in 2 countries. Site status is shown where the registry gives one.
Associated Retina Consultants
Gilbert, Arizona
Associated Retina Consultants, Ltd.
Phoenix, Arizona
Cameron Ria, LLC
Phoenix, Arizona
Retina Macula Institute of Arizona
Scottsdale, Arizona
Retina-Vitreous Associates Medical Group
Beverly Hills, California
Global Research Management
Glendale, California
Retina Associates of Southern California
Huntington Beach, California
Retinal Consultants Medical Group, Inc
Modesto, California
Northern California Retina Vitreous Associates MedicalGroup, Inc.
Mountain View, California
Eye Research Foundation
Newport Beach, California
Retina Consultants of San Diego
Poway, California
Retinal Consultants Medical Group
Sacramento, California
Bay Area Retina Associates - Walnut Creek
Walnut Creek, California
Retina Specialists of Colorado Research, LLC
Denver, Colorado
Coastal Eye Surgeons
Greenwich, Connecticut
Vitreo Retinal Associates - Gainesville
Gainesville, Florida
MedEye Associates
Miami, Florida
Eye Associates of Pinellas
Pinellas Park, Florida
East Florida Eye Institute
Stuart, Florida
Center for Retina and Macular Disease
Winter Haven, Florida
Southeast Retina Center, PC
Augusta, Georgia
Illinois Retina Associates - Oak Park
Oak Park, Illinois
The Eye Care Institute
Louisville, Kentucky
Cumberland Valley Retina Consultants
Hagerstown, Maryland
Ophthalmic Consultants of Boston
Boston, Massachusetts
University of Missouri Health System
Columbia, Missouri
NJRetina
Teaneck, New Jersey
Verum Research, LLC
Eugene, Oregon
Retina Northwest
Portland, Oregon
EyeHealth Northwest
Portland, Oregon
Mid Atlantic Retina - Wills Eye Hospital
Philadelphia, Pennsylvania
Charleston Neuroscience Institute - Charleston
Charleston, South Carolina
Tennessee Retina
Nashville, Tennessee
Austin Clinical Research, LLC
Austin, Texas
Retina Consultants of Texas - Beaumont
Beaumont, Texas
Retina Foundation of the Southwest
Dallas, Texas
Red River Research Partners, LLC - Plano
Plano, Texas
Retinal Consultants of San Antonio
San Antonio, Texas
Retina Consultants of Texas - Schertz
Schertz, Texas
Retina Consultants of Texas-The Woodlands-67575
The Woodlands, Texas
Showing 40 of 44 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.